Biomarkers and surrogate endpoints: Preferred definitions and conceptual framework

被引：4331

作者：

Atkinson, AJ

Colburn, WA

DeGruttola, VG

DeMets, DL

Downing, GJ

Hoth, DF

Oates, JA

Peck, CC

Schooley, RT

Spilker, BA

Woodcock, J

Zeger, SL

机构：

[1] NIH, Off Sci Policy, Bethesda, MD 20892 USA

[2] NIH, Warren G Magnuson Clin Ctr, Bethesda, MD 20892 USA

[3] MDS Harris Inc, Phoenix, AZ USA

[4] Harvard Univ, Sch Publ Hlth, Boston, MA 02115 USA

[5] Univ Wisconsin, Dept Biostat, Madison, WI USA

[6] Axys Pharmaceut, San Francisco, CA USA

[7] Vanderbilt Univ, Dept Med, Nashville, TN USA

[8] Georgetown Univ, Ctr Drug Dev Sci, Washington, DC USA

[9] Univ Colorado, Hlth Sci Ctr, Dept Med, Denver, CO 80262 USA

[10] Pharmaceut Res & Manufacturers Amer, Washington, DC USA

[11] US FDA, Ctr Drug Evaluat & Res, Rockville, MD 20857 USA

[12] Johns Hopkins Univ, Sch Hyg & Publ Hlth, Dept Biostat, Baltimore, MD 21205 USA

来源：

CLINICAL PHARMACOLOGY & THERAPEUTICS | 2001年 / 69卷 / 03期

关键词：

D O I：

10.1067/mcp.2000.113989

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

引用

页码：89 / 95

页数：7

共 30 条

[11] A CONTROLLED TRIAL OF INTERFERON-GAMMA TO PREVENT INFECTION IN CHRONIC GRANULOMATOUS-DISEASE [J].

EZEKOWITZ, RAB .

NEW ENGLAND JOURNAL OF MEDICINE, 1991, 324 (08) :509-516

[12] Surrogate end points in clinical trials: Are we being misled? [J].

Fleming, TR ;

DeMets, DL .

ANNALS OF INTERNAL MEDICINE, 1996, 125 (07) :605-613

[13]

FLEMING TR, 1998, ENCY BIOSTATISTICS, V6, P4425

[14] SLOW RECOVERY OF HUMAN BRAIN MAO-B AFTER L-DEPRENYL (SELEGELINE) WITHDRAWAL [J].

FOWLER, JS ;

VOLKOW, ND ;

LOGAN, J ;

WANG, GJ ;

MACGREGOR, RR ;

SCHLYER, D ;

WOLF, AP ;

PAPPAS, N ;

ALEXOFF, D ;

SHEA, C ;

DORFLINGER, E ;

KRUCHOWY, L ;

YOO, K ;

FAZZINI, E ;

PATLAK, C .

SYNAPSE, 1994, 18 (02) :86-93

[15] STATISTICAL VALIDATION OF INTERMEDIATE END-POINTS FOR CHRONIC DISEASES [J].

FREEDMAN, LS ;

GRAUBARD, BI ;

SCHATZKIN, A .

STATISTICS IN MEDICINE, 1992, 11 (02) :167-178

[16]

HUGHES MD, 1995, J ACQ IMMUN DEF SYND, V10, pS1

[17] SURROGATE MARKERS IN AIDS - WHERE ARE WE - WHERE ARE WE GOING [J].

LAGAKOS, SW ;

HOTH, DF .

ANNALS OF INTERNAL MEDICINE, 1992, 116 (07) :599-601

[18]

Lin DY, 1997, STAT MED, V16, P1515, DOI 10.1002/(SICI)1097-0258(19970715)16:13<1515::AID-SIM572>3.0.CO

[19]

2-1

[20] NEW MOLECULAR END-POINTS AND METHODS FOR ROUTINE TOXICITY TESTING [J].

MACGREGOR, JT ;

FARR, S ;

TUCKER, JD ;

HEDDLE, JA ;

TICE, RR ;

TURTELTAUB, KW .

FUNDAMENTAL AND APPLIED TOXICOLOGY, 1995, 26 (02) :156-173

← 1 2 3 →